Charles Schwab Investment Management Inc Apellis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 996,748 shares of APLS stock, worth $29.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
996,748
Previous 956,362
4.22%
Holding current value
$29.3 Million
Previous $27.6 Million
15.32%
% of portfolio
0.01%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding APLS
# of Institutions
303Shares Held
112MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$458 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$349 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$327 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$288 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$170 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...